Sex: M
Vaccine: MMR
Symptoms: Salivary gland enlargement, Viral titre
Clinical narrative: These results suggest that symptomatic cases do not have protective levels of antibodies to JL and genotype G prior to mumps infection; This literature marketed report had been received from the authors of a published article, titled as stated above, and refers to a 23-year-old male patient. The article aimed that in 2017, a mumps outbreak occurred in military barracks, so serum collected at service entry was used to compare pre-exposure with presumptive vaccine-induced antibody levels from persons who developed mumps (cases) and potentially exposed persons who did not develop mumps (non-cases).  Information regarding the patient's pertinent medical history, concurrent conditions, concomitant therapies and previous drug reactions or allergies was not provided.  On an unknown date, the patient was vaccinated with 2 dose childhood regimen of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (manufacturer unknown) as prophylaxis (dose, route of administration, vaccination scheme frequency, anatomical location, lot number and expiration date were not reported).  On 26-MAR-2012, a sample was collected and showed Jeryl Lynn (JL) titer at 36.0 (units not provided) and genotype G titer at 14.7 (units not provided), CDC IgM was negative (-), Zeus IgG was positive (+) (Zeus Index value: 2.47 (units not provided)), avidity was 43 percent (High). On 14-AUG-2016, a sample was collected and showed JL titer at 29.5 (units not provided) and genotype G titer at 9.9 (units not provided), CDC IgM was negative (-), Zeus IgG was positive (+) (Zeus Index value: 2.08 (units not provided)), avidity was 55 percent (High). On 22-NOV-2016, a sample was collected and showed JL titer at 32.7 (units not provided) and genotype G titer at 11.6 (units not provided), CDC IgM was negative (-), Zeus IgG was positive (+) (Zeus Index value: 2.58 (units not provided)), avidity was 36 percent (High). It was reported that results suggested that symptomatic cases do not have protective levels of antibodies to JL and genotype G prior to mumps infection (mumps antibody test negative).  On 11-APR-2017, the patient was symptomatic and exhibited typical mumps symptoms (parotid/salivary gland swelling, orchitis, fever, malaise).   On 20-APR-2017, the patient received outbreak dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (manufacturer unknown) (dose, route of administration, anatomical location, lot number and expiration date were not reported).  On 28-APR-2017, CDC laboratory classification report confirmed case (C) of mumps. Also, sample collected show JL titer at 3570.4 (units not provided) and genotype G titer at 2530.0 (units not provided), CDC IgM was positive (+), Zeus IgG positive (+) (Zeus Index value: 5.91 (units not provided)), avidity percent quantity not sufficient (for testing) (QNS), and PCR was positive. Other testing and alternative diagnosis were positive cytomegalovirus (CMV) IgG.  The outcome of the event mumps antibody test negative was not provided. The causal relationship between the event mumps antibody test negative and the suspect therapy measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (manufacturer unknown) was considered as related.  Lot # is being requested and will be submitted if received.  This is one of several reports received from the literature.  A copy of the published article is attached as further documentation of the patient's experience.  Literature Report:   US-009507513-2408USA003357: US-009507513-2407USA014510: US-009507513-2408USA003354: US-009507513-2408USA003353: US-009507513-2408USA003361: US-009507513-2408USA003358: US-009507513-2408USA003359: US-009507513-2408USA003360: US-009507513-2408USA003362: US-009507513-2408USA003363: US-009507513-2408USA003355: